COMPUGEN LTD (CGEN)       1.12  -0.02 (-1.75%)

1.12  -0.02 (-1.75%)

IL0010852080 - Common Stock


Fundamental Rating

2

Taking everything into account, CGEN scores 2 out of 10 in our fundamental rating. CGEN was compared to 64 industry peers in the Life Sciences Tools & Services industry. The financial health of CGEN is medium. Also its profitability is quite bad. CGEN is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

0

CGEN has negative profitability rations, so we won't be analyzing them here.
CGEN's Return On Assets of -39.50% is worse than the rest of the industry. The industry average Return On Assets is -13.25%. 83% of the industry peers have a better Return On Assets.

CGEN has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for CGEN.
VS Industry

ROA (-39.5%) VS Industry: 17% outperformed.

-620.54
57.39

Valuation

Valuation Rating

2

When comparing the price book ratio of CGEN to the average industry price book ratio of 2.39, CGEN is valued rather cheaply.
When comparing the current price to the book value of CGEN, we can conclude it is valued correctly. It is trading at 1.22 times its book value.

CGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
VS Industry

Price/Book (1.22) VS Industry: 73% outperformed.

52.20
0.23

Growth

Growth Rating

2

Measured over the past 5 years, CGEN shows a very strong growth in Revenue. The Revenue has been growing by 53.24% on average per year.
The Earnings Per Share is expected to decrease by -2.60% on average over the next 5 years.
Based on estimates for the next 5 years, CGEN will show a decrease in Revenue. The Revenue will decrease by -6.85% on average per year.

CGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.00%.
The Revenue for CGEN has decreased by -100.00% in the past year. This is quite bad
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -15% -23.57% -12.85% -17.91% -2.6%
Revenue53.24% -30.41% -100% -100% -41.42% -13.43% -6.85%

Health

Health Rating

4

CGEN has a Current Ratio of 6.16. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
When comparing the Current Ratio to an average industry Current Ratio of 4.94, CGEN is better placed than the average industry peer to meet its short term obligations.
A Quick Ratio of 6.16 indicates that CGEN has no problem at all paying its short term obligations.

When comparing the Quick Ratio to an average industry Quick Ratio of 4.34, CGEN is better placed than the average industry peer to meet its short term obligations.
With a Debt to Equity ratio of 0.00, CGEN is doing better than the averages in the industry. The industry average is at 0.11.
The Piotroski-F score of CGEN is 2.00. This is a very weak score and indicates problems in health and profitability for CGEN.
VS Industry

Debt/Equity (0) VS Industry: 71% outperformed.

3.88
0.00

Quick Ratio (6.16) VS Industry: 69% outperformed.

0.23
40.60

Current Ratio (6.16) VS Industry: 65% outperformed.

0.23
40.60

Dividend

Dividend Rating

0

No dividends for CGEN!.

CGEN Daily chart

COMPUGEN LTD1.12

NASDAQ:CGEN (12/7/2022, 2:30:01 PM)-0.02 (-1.75%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 02-22 2023-02-22
Ins Owners N/A Inst Owners 25.46%
Market Cap 97.02M Analysts 84.62
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 1.22
EV/EBITDA -0.31
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -15% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -100%
EPS Next Y -23.57% EPS Next 2Y -12.85%
EPS Next 3Y -17.91% EPS Next 5Y -2.6%
Revenue growth 1Y -100% Revenue growth 3Y -30.41%
Revenue growth 5Y 53.24% Revenue growth Q2Q -100%
Revenue Next Year -100% Revenue Next 2Y -41.42%
Revenue Next 3Y -13.43% Revenue Next 5Y -6.85%
Health
Current Ratio 6.16 Quick Ratio 6.16
Altman-Z N/A F-Score 2
Debt/Equity 0 WACC 7.97%
ROIC/WACC N/A
Profitability
ROA -39.5% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA